Lurbinectedin
- Generic Name
- Lurbinectedin
- Brand Names
- Zepzelca, 赞必佳
- Drug Type
- Small Molecule
- Chemical Formula
- C41H44N4O10S
- CAS Number
- 497871-47-3
- Unique Ingredient Identifier
- 2CN60TN6ZS
- Background
Lurbinectedin is a DNA alkylating agent that has been investigated in the treatment of a variety of cancers, including mesothelioma, chronic lymphocytic leukemia (CLL), breast cancer, and small-cell lung cancer (SCLC). It is a derivative of the marine-derived agent ecteinascidin (trabectedin), an anticancer agent found in extracts of the tunicate Ecteinascid...
- Indication
Lurbinectedin is indicated for the treatment of adult patients with metastatic small-cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.
- Associated Conditions
- Metastatic Lung Small Cell Carcinoma
- Associated Therapies
- -
Clinical Pharmacokinetic Study of Lurbinectedin in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Impairment
- First Posted Date
- 2021-11-01
- Last Posted Date
- 2023-11-27
- Lead Sponsor
- PharmaMar
- Target Recruit Count
- 24
- Registration Number
- NCT05101265
- Locations
- 🇪🇸
Hospital Universitari Vall d'Hebron, Barcelona, Cataluña, Spain
🇪🇸Hospital General Universitario Gregorio Marañón, Madrid, Spain
🇪🇸Hospital Universitario Virgen de la Victoria, Málaga, Andalucía, Spain
Lurbinectedin + Doxorubicin In Leiomyosarcoma
- Conditions
- Interventions
- First Posted Date
- 2021-10-29
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 62
- Registration Number
- NCT05099666
- Locations
- 🇺🇸
Mayo Arizona, Phoenix, Arizona, United States
🇺🇸Mayo Jacksonville, Jacksonville, Florida, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-10-25
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 690
- Registration Number
- NCT05091567
- Locations
- 🇺🇸
Florida Cancer Specialists - Fort Myers (Broadway), Fort Myers, Florida, United States
🇺🇸Florida Cancer Specialist, North Region, Saint Petersburg, Florida, United States
🇺🇸SCRI Florida Cancer Specialists PAN, Tallahassee, Florida, United States
Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid Tumors
- First Posted Date
- 2021-10-08
- Last Posted Date
- 2021-10-08
- Lead Sponsor
- PharmaMar
- Target Recruit Count
- 8
- Registration Number
- NCT05072106
- Locations
- 🇪🇸
Fundación Jiménez Diaz, Madrid, Spain
🇪🇸Hospital de Sanchinarro, Madrid, Spain
Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2021-09-13
- Last Posted Date
- 2022-02-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT05042934
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC)
- Conditions
- First Posted Date
- 2021-05-20
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 300
- Registration Number
- NCT04894591
- Locations
- 🇺🇸
Research Institute & Clinical Alliance, Houston, Texas, United States
🇺🇸Clearview Cancer Institute, Huntsville, Alabama, United States
🇺🇸Pacific Cancer Medical Center, Inc, Anaheim, California, United States
Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers
- Conditions
- Interventions
- First Posted Date
- 2021-03-17
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 120
- Registration Number
- NCT04802174
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC
- Conditions
- Interventions
- First Posted Date
- 2020-10-30
- Last Posted Date
- 2024-04-02
- Target Recruit Count
- 9
- Registration Number
- NCT04610658
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Advent Health - Celebration, Kissimmee, Florida, United States
Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 106
- Registration Number
- NCT04607954
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer.
- Conditions
- Interventions
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Antonio Calles Blanco
- Target Recruit Count
- 28
- Registration Number
- NCT04358237
- Locations
- 🇪🇸
Hospital Vall D´Hebrón, Barcelona, Spain
🇪🇸ICO - Instituto Catalán de Oncología, Barcelona, Spain
🇪🇸START - Phase I Unit - HN San Chinarro, Madrid, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.